Search

Pediatric bacterial conjunctivitis is a common, highly contagious infection that requires prompt and effective therapy. In the treatment of bacterial conjunctivitis, gatifloxacin ophthalmic solution 0.3% (Allergan, Inc.) is associated with high clinical cure rates and a low rate of mostly mild adverse effects. In vitro, gatifloxacin ophthalmic solution 0.3% demonstrates bactericidal activity against a broad spectrum of ocular pathogens associated with bacterial conjunctivitis, including many that are resistant to other antibiotics. Gatifloxacin was designed to be less likely than earlier generations of antibiotics to promote antibiotic resistance and is associated with high susceptibility rates. These properties make gatifloxacin an appropriate choice for conditions that require safe and effective treatment in this age of increasing antibiotic resistance.